You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy
|
|---|---|
| Published in |
Blood, August 2015
|
| DOI | 10.1182/blood-2015-03-630012 |
| Pubmed ID | |
| Authors |
Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J Rummel, Rainer Haas, Guido Kobbe |
| Abstract |
Bcl-2/IgH-rearrangements can be quantified in follicular lymphoma (FL) from peripheral blood (PB) by PCR. The prognostic value of Bcl-2/IgH levels in FL remains controversial. We therefore prospectively studied PB Bcl-2/IgH levels from 173 first-line FL patients who were consecutively enrolled, randomized and treated within the multicenter phase 3 clinical trial NHL1-2003 comparing bendamustine-rituximab (B-R) with CHOP-rituximab (R-CHOP). From April 2005 to August 2008 783 pre- and post- treatment PB samples were quantified by qPCR. At inclusion 114 patients (66%) tested positive and 59 (34%) were negative for Bcl-2/IgH. High pre-treatment Bcl-2/IgH levels had an adverse effect on PFS compared to intermediate or low levels (high vs. intermediate: HR 4.28, 95% CI 1.70 - 10.77; p=0.002; high vs. low: HR 3.02, 95% CI 1.55 - 5.86; p=0.001). No PFS difference between treatment arms was observed in Bcl-2/IgH-positive patients. A positive post-treatment Bcl-2/IgH status was associated with shorter PFS (8.7 months vs. not reached; HR 3.15, 95% CI 1.51-6.58; p=0.002). By multivariate analysis, the pre-treatment Bcl-2/IgH level was the strongest predictor for PFS. Our data suggest that pre- and post- treatment Bcl-2/IgH levels from PB have significant prognostic value for PFS in FL receiving first-line immuno-chemotherapy. This trial was registered to www.clinicaltrials.gov as #NCT00991211 and the German Federal Institute for Drugs and Medical Devices as #BfArM-4021335. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Denmark | 1 | 25% |
| Mexico | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 64 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 15% |
| Other | 9 | 14% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 5 | 8% |
| Student > Master | 5 | 8% |
| Other | 12 | 18% |
| Unknown | 17 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 46% |
| Agricultural and Biological Sciences | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 4 | 6% |
| Unknown | 20 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2015.
All research outputs
#15,168,167
of 25,371,288 outputs
Outputs from Blood
#25,997
of 33,239 outputs
Outputs of similar age
#133,854
of 275,737 outputs
Outputs of similar age from Blood
#123
of 230 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,239 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,737 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 230 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.